Rewind Therapeutics

Rewind Therapeutics is developing novel re-myelinating therapies for patients suffering from Multiple Sclerosis and other myelin-related diseases. In close collaboration with KU Leuven’s Centre for Drug Design and Discovery (CD3), Axxam S.p.A. and a world-class academic network, Rewind Therapeutics aspires to advance innovative first-in-class therapies to the clinic. Rewind Therapeutics is based in Leuven, Belgium.

Team Member
more about
Cheryl Zimberlin
Investment Director
Latest News Entry
Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor

Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that it has raised additional funding, with Sunstone Life Science Ventures A/S joining as a new investor and with participation of existing investors Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven.

Rewind Therapeutics appoints leading neuroscience drug developer Ian J. Reynolds as Chief Executive Officer

Rewind Therapeutics (“Rewind”), a private Belgian biotech company developing innovative first-in-class therapies for myelin-related diseases announces the appointment of Ian J. Reynolds as its Chief Executive Officer (CEO)

Rewind Therapeutics secures 15.2 M EURO to develop novel remyelination therapies
all portfolio news